FDA rejects Alkermes' NDA for antidepressant ALKS 5461; shares down 4% after hours - Seeking Alpha

Submitted by Anonymous (not verified) on Fri, 02/01/2019 - 21:10

FDA rejects Alkermes' NDA for antidepressant ALKS 5461; shares down 4% after hours  Seeking AlphaAlkermes plc (ALKS) has received a CRL in response to its marketing application seeking approval for ALKS 5461 for the adjunctive treatment of major depres.